The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy

Inclusion Criteria: 1.30 years ≤ 75 years of age, regardless of sex; 2.Clinically confirmed or clinically probable MSA-P; 3.Poor response to levodopa; 4.MSA-related motor symptom onset ≤5 years at first visit; 5.Walking ≥10 meters independently or with a walking aid; 6.Expected survival of ≥1 year, as determined by the investigator; 7.Signed informed consent. Exclusion Criteria: 1. Head MRI at screening showing evidence of other CNS lesions consistent with a diagnosis of neurodegenerative disease other than MSA; 2. Patients with MMSE scores indicative of dementia prior to enrolment (≤17 points for illiterate individuals, ≤20 points for individuals with elementary school education, ≤24 points for individuals with junior high school education or higher) or those with a prior confirmed diagnosis of dementia; 3. Head MRI at screening showing other significant pathological findings including but not limited to: cerebral hemorrhage, acute phase of cerebral infarction, aneurysm, vascular malformation, infectious lesion, brain tumor or other space-occupying lesion (meningiomas or arachnoid cysts with a maximum diameter of \<1 cm need not be excluded); 4. Presence of immune disorders that are inadequately controlled or require treatment with biological agents; 5. Known history of allergy to biological agents such as proteins and cell products; 6. Patients who have received any vaccination within 1 month; 7. Patients with pre-existing, clearly diagnosed malignant tumor or being treated with anti-tumor drugs; 8. Patients with a history of clearly diagnosed epilepsy or taking antiepileptic drugs; 9. Presence of lumbar spine disease and deformity or other contraindications to lumbar puncture; 10. Patients with abnormal coagulation function prior to enrolment (e.g., platelet count \<100 × 10E9/L; prothrombin time \[PT\] \>3 s), previous diagnosis of coagulation disorders such as hemophilia, and patients currently receiving more than two types of antiplatelet medication; 11. Contraindications to MRI (e.g. claustrophobia, internal placement of pacemakers or paramagnetic metals, etc.); 12. With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR\<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4); 13. Hepatitis B active infection (hepatitis B surface antigen positive and/or serum HBV DNA positive or serum HBV DNA \> 2 × 10E8 IU/ml; 14. Hepatitis C virus antibody positive or history of positive test; 15. Positive HIV test or history of positive test; 16. Patients with a combined history of alcohol or drug abuse or alcohol or drug dependence within 2 years; 17. Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent; 18. Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant; 19. Patients who are participating in other interventional studies or using other investigational biological agents, drugs, or devices, and patients who have used other experimental drugs within 1 month or within 5 drug half-lives; 20. Unable to be cooperative and complete the follow-up due to other reasons. 21. Patients who, in the opinion of the investigator, are not suitable for participation in this trial.